Becker Hewes: Yes, sure. Thanks. Just a reminder that, we’re here to make a difference in the patient’s lives for years to come by improving their symptoms in ISM. And AYVAKIT has set a tremendously high bar in this part of the disease. Another reminder is that avapritinib elenestinib and bezeclatinib are all equally potent against TTD816V. And for any new agent coming in, it’s necessary to demonstrate broad symptom impact that doesn’t come at the price of a worse safety profile. And as a reminder at 25 milligrams of AYVA this was evident with no Grade 3 adverse events in Part 1 and an amazing safety profile that we saw in Pioneer. And as Kate said, a point of the elenestinib program is to expand and enhance our leadership in SM and really address all parts of the disease. At ASH, we’ll show data showing elenestinib is active and safe and in patients, with indolent systemic mastocytosis and an amazing candidate for development in this space.
Operator: Our next question comes from Michael Schmidt with Guggenheim. Your line is open.
Q – Michael Schmidt: Hey, guys. Thanks for taking the question. Congrats on the great AYVAKIT sales this quarter. Perhaps, a slight follow-up on the prior question for elenestinib. What are your latest thoughts on next development steps after ASH? How should we think about the opportunity for this drug, beyond what AYVAKIT is already addressing? And then secondly, also on the pipeline wondering, how we should think about the CDK2 program at this point? I know you’re very excited about it. I was just curious where you stand with the study there.
Kate Haviland: Yes, Michael, thank you for those questions. Christie, — will you take the question on elenestinib and then Becker, will you going in on CDK2?
Christy Rossi: Sure. So, thanks Michael for the question. The role that elenestinib plays in our portfolio, as I said is really extending and expanding our franchise over the long term. AYVAKIT is very much the cornerstone. And the bar for any new therapy is AYVAKIT and we’re very acutely aware that that bar, as I said, gets higher every day that we’re in the market. We are excited about our potential to develop elenestinib, based on the deep understanding that we have of this disease. How we can bring it forward in clinical development, to develop a data set that is bespoke and we’ll really speak to the role and the efficacy and safety that this therapy can play in SM again over the long term. So ASH, we really see as a first step in demonstrating that the molecule is safe, it’s active.
How we bring it forward will unfold frankly in months and years coming out of ASH, based on the knowledge that we have. And we think that we are in frankly, a unique and unparalleled position to be able to develop a next-generation therapy in SM, based on the proprietary knowledge that we have.
Kate Haviland: I think on CDK2
Becker Hewes: Sure. So as you remember at ASCO, we presented data showing the unique tolerability profile of BLU-222 compared to others in the field with very little impact on hematology and any other side effect profile really that would be limited its combination with ribociclib. So the main focus is in breast cancer and that’s what really drives the value for any CDK2 program. We have — we believe that we’ve closed the gap with Pfizer and the feedback we’re getting from investigators is that BLU-222, is really leading the pack right now with great tolerability data. And also, we’ve shown the efficacy starting to emerge. We’ve shown the response in breast cancer and we continue to enroll patients in breast cancer and other indications. We’re still in dose escalation. We have begun the combination as we’ve indicated, and we look forward to sharing more data next year.
Operator: Our next question comes from Derek Archila with Wells Fargo. Your line is open.
Derek Archila: Hey, good morning and congrats on the progress. Thanks for taking our question. So it’s a very interesting commentary on the 2024 OpEx. I just want to understand, do you see continued rationalization prioritization beyond 2024 meaning, does out-year spend become lower? And can you get more aggressive on that $100 million as you indicated for 2024? Thanks.
Kate Haviland: Yes. Thanks, Derek for the question. We will be providing more view, on how we’re thinking about operating expenses in a kind of a more official way on our Q4 call. Really I think what Mike was trying to talk about is just the fact that, as we look at consensus out there the numbers are really well off where our plan is. And I think from where we stand when we see the ramping revenues at AYVAKIT, and we think not just about 2024, but this path to $1 billion market opportunity and north of that as we continue to launch. We see a really compelling profile for the company. Mike, do you want to provide some more color?
Mike Landsittel: Yes. I think Kate’s, right, like the commentary we provided was specific to 2024 guidance because we think that’s just well of consensus – 2024 consensus, because we think that’s well off base. We’re obviously not providing specific guidance on 2024 OpEx right now, but fundamentally it’s going to come down versus 2023. And I think importantly is our total cash burn is going to come down significantly in 2024. And those are the guidelines that we’re pointing to right now. We will in early 2024 spend more time talking about our capital allocation strategy. And I think that will give more color as to what Kate was saying how do we think about the longer term investments that we’ll be making in the portfolio? How do we think about partnerships? And I think it’s really exciting, but we feel we’re in a very strong place financially in 2024 and beyond.
Operator: We now turn to Ami Fadia with Needham. Your line is open.
Ami Fadia: Hi, good morning. Let me add, my congratulations to the great launch in ISM. Perhaps, if you could add any color around where the patients are and maybe concentration of patients within physician offices. I think you mentioned briefly that you’re starting to see prescribers that have the potential for meaningful depth of prescribing. But maybe you can give us some color around how concentrated these patients are? That would be helpful. And just a follow-up on elenestinib. Can you talk about how much of duration of data in a number of patients we could expect to see at the ASH update? Thank you.
